DBDmitry Bulaev

Dmitry Bulaev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmitry Bulaev has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Guy Fagherazzi

    Deep Digital Phenotyping Research Unit, Department of Precision Health Luxembourg Institute of Health Strassen Luxembourg

    2 shared publications
  • Marc Paul O Sullivan

    Transversal Translational Medicine, Luxembourg Institute of Health, Luxembourg

    2 shared publications
  • Michel Vaillant

    Competence Centre for Methodology and Statistics, Department of Medical Informatics, Luxembourg Institute of Health, Luxembourg

    2 shared publications
  • Alexey Kolodkin

    Affiliation Luxembourg Institute of Health (LIH), Strassen, Luxembourg

    1 shared publication
  • Aljosa Celebic

    Department of Medical Informatics, LIH, Strassen, Luxembourg

    1 shared publication
  • Andreas Wieser

    Affiliations Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, Munich, Germany, German Center for Infection Research (DZIF), Munich, Germany, Max Von Pettenkofer Institute, Faculty of Medicine, LMU Munich, Munich, Germany

    1 shared publication

Latest Publications

  • Open Access

    Cognitive Profiling and Validation of a Digital Cognitive Assessment Tool in Post-COVID-19 Condition: Protocol for a Single-Center, Cross-Sectional Study (DigiCog Study)

    by Elena Lacomba-Arnau, Rita Da Rocha Oliveira, Sara Monteiro, Claire Pauly, Michel Vaillant, Aljosa Celebic, Dmitry Bulaev, Aurélie Fischer, Guy Fagherazzi, Gerardo Fernandez, et al.

    Background: Cognitive impairment is among the most frequently reported and disabling persistent symptoms following SARS-CoV-2 infection. Despite growing evidence of its prevalence, the characterization of domain-specific cognitive profiles and the identification of modifiable factors influencing cognitive outcomes in post-COVID-19 condition (PCC) remains scarce. Digital cognitive assessment tools have emerged as scalable and examiner-independent alternatives to traditional neuropsychological testing, but their validation in post-infectious contexts is still limited. Objective: The DigiCog study aims to characterize cognitive profiles associated with PCC, to evaluate a novel digital cognitive assessment technology (ViewMind, VMTech) against standardized neuropsychological measures, and to explore the potential role of cognitive reserve (CR) proxies in shaping cognitive outcomes following SARS-CoV-2 infection. Methods: DigiCog is a single-center cross-sectional study conducted within the Luxembourgish Predi-COVID cohort ( NCT04380987 ). Participants aged 25–65 years, with and without persistent COVID-19 symptoms, are invited to participate. Cognitive assessments are performed during face-to-face sessions by trained nurses and neuropsychologists using both the VMTech device and standardized neuropsychological tests. Additional data on PCC symptom status, CR, sociodemographic characteristics, fatigue, and psychological factors are also collected. Agreement between digital and standard cognitive assessments will be evaluated using Cohen’s kappa coefficient, with sensitivity, specificity, and receiver operating characteristic analyses as secondary measures. Cognitive performance will be compared between participants with and without PCC, and associations with CR proxies will be explored. Results: Participant recruitment began in May 2023. As of March 2025, 199 participants had been enrolled. Data collection has been completed. Data processing and statistical analyses are ongoing. Conclusions: The DigiCog study will provide new insights into cognitive functioning in PCC and evaluate the validity of a novel digital cognitive assessment approach. By integrating neuropsychological testing, digital assessment, and cognitive reserve, the study may inform scalable and more personalized approaches to cognitive screening and monitoring in post-infectious conditions. Study registration: ClinicalTrials.gov NCT06391970 ; Luxembourg National Research Ethics Committee approval No. 202208/05.

  • Open Access

    Data flow in the Luxembourg COVID-19 joint initiative: a blueprint for data-driven translational medicine

    by Irina Balaur, Piyapong Khumrin, Soumyabrata Ghosh, Dmitry Bulaev, Priyanka Mendon, Kavita Rege, Milena Despotovic, Sarah Peter, Rajesh Rawal, Jochen Ohnmacht, et al.

    CoVaLux is a unique national scientific consortium studying COVID-19, vaccination, and long-term health outcomes in Luxembourg. The program combines data from multiple research initiatives in a secure environment, establishing an effective framework for data management and analysis. Here, we delineate the development of the CoVaLux data flow, addressing critical requirements and showcasing how CoVaLux can serve as a model for similar medical research projects worldwide, particularly in pandemic preparation.

  • Open Access

    Waning of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in 2020: A 12-month-evaluation in three population-based European studies

    by Sophie Novelli, Christina Reinkemeyer, Dmitry Bulaev, Marc Paul O’sUllivan, Chantal J. Snoeck, Armin Rauschenberger, Carmelite Manto, Alexey Kolodkin, Soumyabrata Ghosh, Venkata Satagopam, et al.

    Objectives: We described waning in anti-SARS-CoV-2 IgG in adult general populations infected during the first wave of the COVID-19 pandemic in 2020 across three European countries. Methods: Coordinated analyses were conducted separately in three population-based cohorts with complementary follow-up schedules: the KoCo19 (Germany), EpiCov (France), and CON-VINCE (Luxembourg) cohorts. Serological follow-up was based on the anti-SARS-CoV-2 ELISA-S IgG (Euroimmun) assay. We selected all adults aged 18–79 who had a positive serology (IgG optical density (OD) ratio ≥1.1) between February and July 2020, and at least one subsequent IgG measurement within the following 12 months, while still non-vaccinated. Results: The proportion of seroreversion was 0% within the four first months, based on Koco19 data (n = 65 participants). In the longer term, 31.3% of participants had seroreverted at 6 months (95%CI: 24.4–39.1) (based on EpiCov data, n = 599), 31.3% (95%CI: 11.0–58.7) at 12 months (based on CON-VINCE data, n = 16). From EpiCov data, both baseline low IgG levels and seroneutralization negativity remained predictive of seroreversion in multivariable analysis. Conclusion: From population-based cohorts, anti-S IgG levels remained stable during the first 4 months following SARS-CoV-2 infection. Most of the decay occurred afterward; nearly one-third of people seroreverted 6 and 12 months later. Low IgG levels and seroneutralization negativity were independent predictors of seroreversion.